Candidiasis Drugs Market Outlook:
Candidiasis Drugs Market size was valued at USD 2.6 billion in 2025 and is projected to reach USD 4.9 billion by the end of 2035, rising at a CAGR of 7.5% during the forecast period, i.e., 2026-2035. In 2026, the industry size of the candidiasis drugs market is estimated at USD 2.8 billion.
The increasing occurrence rate of bloodstream infections, fungal infections, particularly among immunocompromised populations around the world, is the primary driver behind the robust growth in the candidiasis drugs market. Also, there has been a shift towards outpatient care and the growing prevalence of hospital-acquired infections, which is remarkably expanding the demand for effective antifungal treatments. NIH in May 2023 revealed that in the U.S., approximately 37% of newborns may develop oral thrush within the first few months of life, wherein children using inhaled corticosteroids also exhibit a higher incidence of oral candidiasis.
Furthermore, IJID Regions in September 2025 stated that recurrent vulvovaginal candidiasis affects around 6% to 9% of women across all nations and imposes a huge burden on Uganda’s healthcare system. Besides, the annual economic cost was valued at USD 75.7 million, which is equal to 11.22% of national health spending. It further stated that the direct medical costs made up 71.5% of the total, while the average cost per patient was USD 70.29, about 7% of per-capita GDP, wherein the key risk factors are HIV, hormonal contraceptives, and antibiotic use.
